CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

CEL-SCI Trading Up 6.9 %

Shares of CVM stock opened at $0.45 on Monday. The stock has a 50-day simple moving average of $0.48 and a 200 day simple moving average of $0.78. CEL-SCI has a fifty-two week low of $0.33 and a fifty-two week high of $2.50. The stock has a market capitalization of $33.04 million, a P/E ratio of -0.87 and a beta of 0.69. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Calton & Associates Inc. bought a new position in CEL-SCI during the third quarter valued at about $50,000. Geode Capital Management LLC boosted its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares in the last quarter. Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after buying an additional 54,900 shares in the last quarter. Finally, Plotkin Financial Advisors LLC bought a new position in CEL-SCI during the third quarter valued at about $98,000. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.